Found 97 Vision Loss trials
A listing of Vision Loss medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Achromatopsia is an inherited retinal disorder characterized by markedly reduced visual acuity, nystagmus, photoaversion (intolerance to bright light), a small central scotoma, eccentric viewing, and complete or severe loss of color discrimination. The genetic mutations of the disease can be established in the majority of individuals. Approximately 25% are caused …
This phase II trial investigates how well adding hydroxychloroquine to the standard treatment of dabrafenib and trametinib works to overcome resistance and delay disease progression in treating patients with stage IIIC or IV BRAF V600E/K melanoma. Giving hydroxychloroquine together with dabrafenib and trametinib may work better than dabrafenib and trametinib …
This open-label study is designed to evaluate the long-term safety and tolerability of acoramidis in participants with ATTR-CM, administered on a background of stable heart failure therapy. This study follows the randomized, double-blind, placebo-controlled Study AG10-301 which was designed to examine safety and efficacy in this same population.
Phase 2b, double-blind, placebo-controlled, parallel group study to provide data on efficacy, safety, tolerability and PK of vupanorsen administered subcutaneously at various doses and regimens with patients with dyslipidemia. Patients will participate for approximately 10 months, and will have blood draws, physical exams, ECGs, and MRIs.
The purpose of this study is to compare the effects of atezolizumab plus tiragolumab versus atezolizumab plus placebo or double placebo on subjects with esophageal cancer who have had at least 2 cycles of chemoradiotherapy without progression of their disease. Subjects with unresectable, locally advanced esophageal cancer will receive either …
The purpose of this study is to compare the usual treatment alone to using one year of olaparib. We will enroll subject who have been diagnosed with pancreatic cancer and have undergone surgery to remove the cancer. Only patients who are found to have a BRCA1, BRCA2 or PALB2 mutation …
Penn Medicine patients already participating in protocol INS1007 301 will be invited to participate in this study. The Pharmacokinetic (PK) portion of this substudy is designed to evaluate the amount of brensocatib present in your blood at certain time periods before and after the study drug is administered, and the …
The purpose of this study is to compare the effects, good or bad, of idasanutlin plus cytarabine (chemotherapy) versus placebo (an inactive substance that looks like idasanutlin) plus cytarabine on patients with relapsed or refractory Acute Myeloid Leukemia (AML) to find out which is better.
Please choose between Voice or SMS based delivery of verification code
or